Robert H. Lurie Cancer Center
Robert H. Lurie Cancer Center
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit) | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast cancer, breast disorder, breast neoplasm, carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, kidney cancer, kidney disorder, male reproductive organ cancer, male reproductive system disorder, malignant colon neoplasm, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, rectal cancer, rectal disorder, rectal neoplasm, renal cell carcinoma, skin disorder, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Active, not recruiting | Not applicable | 2026-10-05 | NCT05056077 | |
| Defining the Ablative Dose for Y-90 TARE | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Margins of Excision, Morphological and Microscopic Findings, Neoplasms by Histologic Type, Neoplasms by Site, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-09-15 | NCT07586046 | |
| Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, acute myeloid leukemia with 11q23 abnormalities, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 | 2025-10-21 | NCT03513484 |